The CGM market is an exciting, fast-growing, multibillion-dollar medtech sector, according to our new Medtech Market ...

On top of this wonderful healthcare business, Abbott, like Coca-Cola, has made rewarding shareholders part of its strategy.

These companies have already handsomely rewarded longtime shareholders, and it's not too late to join the party.

According to Precedence Research, the global glucose biosensors market size will grow from USD 10.71 billion in 2025 to nearly USD 23.08 billion by 2034, with an expected CAGR of 8.91% from 2025 to ...

The latest version of Abbott's FreeStyle Libre continuous glucose monitor is now available via the NHS to eligible people with diabetes in the UK. Abbott's wearable FreeStyle Libre 3 device – which is ...

An Institute for Clinical and Economic Review report concluded that the GLP-1 drugs tirzepatide and semaglutide (Ozempic, ...

A review of 17 studies reports a fourfold increase in risk and ties worse hearing to longer disease duration and higher HbA1c ...

Walmart will become the first U.S. retailer to sell Abbott’s continuous glucose monitoring device as the medtech giant looks to broaden its sales potential for its growing business unit. Abbott has ...

Insulet reported Omnipod revenue of $699.2 million for the third quarter of 2025, up 31% over the same quarter in 2024 ...

Growth is driven by increasing demand for personalized treatment, improved delivery technologies, and biosimilars, despite challenges like high costs and regulatory demands Rapid Acting Insulin Market ...

Lingo is Abbott’s latest venture into bio-wearable technology, designed to help users understand their unique metabolic ...

Tandem Diabetes Care Inc (TNDM) achieves record third-quarter sales, driven by strategic initiatives and international ...